Search

everythinglearnresearchcommunity

for

Search:↓

HMI 115 is being discussed as a potential hair loss treatment, with skepticism due to past disappointments like cosmeRNA, brezula, and pyrilutamide. The user is questioning if they should be hopeful for new developments in the next six years.

There are no updates on GT20029, and concerns about its safety and effectiveness remain. The phase III trial has not started, and there are no new studies or data releases.

The conversation discusses using TH16, a topical melatonin with resveratrol, and stemoxydine for hair maintenance, avoiding finasteride and minoxidil due to side effects. The user is considering a low-dose topical finasteride despite sensitivity.

A 17-year-old is considering starting finasteride and minoxidil for hair loss, despite concerns about potential side effects and the impact on development. The user is advised to check if puberty is complete and to consider using only minoxidil until adulthood.

The conversation is about identifying the vehicle used in the Breezula (clascoterone) trial for hair loss. No specific treatments were mentioned.

The conversation is about using micro needling and PTD-DBM for hair loss treatment. The user applies PTD-DBM drops on weekdays and performs micro needling weekly.

Hair loss discussion includes potential HMI-115 treatment. Topical mucuna pruriens shows good results, blocking prolactin possibly more important than blocking DHT.

The user is generally happy with their hair transplant results but has concerns about graft density and placement, particularly on the left temple and hairline. They are using finasteride and minoxidil inconsistently, plan to add Priorin, and are considering microneedling and PRP sessions for future care.

A 21-year-old male uses minoxidil, finasteride, and dutasteride for hair loss but still experiences progression with high DHT levels. Suggestions include increasing dosages, checking for deficiencies, considering a hair system, or consulting a specialist.

A user's 12-month progress using RU58841, dutasteride, and minoxidil for hair loss. The user is open to answering questions via direct message.

The user is experiencing hair loss and is using Minoxidil once a day. They suspect Vitamin D deficiency and Seborrheic Dermatitis might be contributing factors.

The conversation is about seeking updates on the hair loss treatment RCH-01, specifically its next phase and any news from Shiseido. The user recalls someone being in contact with a researcher or company representative.

A 17-year-old is experiencing rapid hair loss over two weeks and is advised that treatments like minoxidil and finasteride can help. It's noted that lighting and angles can affect the appearance of hair loss, and a guide is recommended for further advice.

An 18-year-old male switched from topical finasteride and minoxidil to oral dutasteride for diffuse hair loss and saw improvement without side effects, despite experiencing scalp itch and shedding. Commenters noted significant hair regrowth and were surprised by his young age and appearance.

OP used 1mg finasteride for 4 years, then had a hair transplant, and for the past 6 months has been using 0.5mg dutasteride and 2.5mg oral minoxidil twice daily. The treatments resulted in significant hair density and thickness improvement.

TDM-105795 showed promising hair growth results, with higher efficacy than placebo and minimal side effects. It activates dormant hair follicle stem cells and may maintain gains without immediate loss, unlike minoxidil.

The user is using a combination of finasteride, dutasteride, oral and topical minoxidil, PRP, and stem cell treatments for hair loss. They report slowed shedding and new vellus hairs on the hairline, questioning if they are a strong responder to the treatment.

The conversation discusses hair loss and the use of Dutasteride for treatment. One participant strongly supports the use of Dutasteride.

19-year-old with Lichen Planopilaris tried various treatments unsuccessfully. Now considering hair systems, seeking experiences and opinions.

PP405 shows promise for hair regrowth by manipulating stem cell characteristics and lactate dehydrogenase, with Phase 2a trials pending. Google Ventures' $15M investment suggests confidence, but results and market availability remain uncertain.

User seeks Procyanidin B2 supplement source and asks for dosage comparison. Another user requests study details and apple type importance.

EDHARRINGTON's journey to regrow his hair using finasteride, topical minoxidil, and micro-needling treatments over 4 years, with others commenting their support and admiration for his results.

A 17-year-old is concerned about hair loss and shares photos for opinions. A user responds that the hair looks normal but is hard to assess from the images.

Female with PCOS experiences receding and thinning hair, wants dutasteride instead of spironolactone. Discusses desire to reduce DHT without losing libido.

The conversation discusses a 13-month hair loss treatment update using dutasteride, minoxidil, nizoral, and a 1.5mm derma roller, with the original poster reporting no side effects and some improvement in hair thickness. Participants request before-and-after pictures with consistent hairstyles to better assess the treatment's effectiveness.

GHK-Cu is a potent inhibitor of the type 1 5-alpha reductase enzyme in hair follicles, which may reduce hair loss without the side effects associated with type 2 5-alpha reductase inhibitors. The user previously experienced side effects with 5-alpha reductase inhibitors and is considering GHK-Cu as an alternative.

The conversation is about a 17-year-old experiencing severe hair thinning and the advice given is to see a dermatologist or doctor to check for underlying health issues or to start treatment early if it's male pattern baldness.

A 17-year-old is experiencing early hair thinning and is considering oral minoxidil while being cautious about finasteride due to side effects. They seek advice on hair maintenance and plan to consult a doctor before using DHT blockers.

TDM-105795 is a potential hair growth stimulant that works differently from minoxidil and could be used alongside it for enhanced growth. It completed phase 2 trials in 2024, with a medium to high chance of release in 2026, but lacks recent updates or phase 3 trial information.

A 22-year-old with high estradiol levels is considering starting finasteride for hair loss. They have an upcoming endocrinologist appointment to discuss whether they should proceed with the treatment.